<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Heparin" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Heparin</book-part-id>
      <title-group>
        <title>Heparin</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>11</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="HematologicGrowthFac" document-type="chapter">Hematologic Growth Factors</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Heparins" document-type="chapter">Heparins</related-object>
    </book-part-meta>
    <body>
      <sec id="Heparin.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Heparin.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Standard or unfractionated heparin is a complex mixture of naturally occurring glycosaminoglycans and is used as an anticoagulant to treat venous thrombosis or to prevent thrombosis in high risk patients. Heparin therapy is associated with frequent elevations in serum aminotransferase levels that are typically transient and not associated with clinical symptoms or significant liver injury.</p>
        </sec>
        <sec id="Heparin.Background">
          <title>Background</title>
          <p>Heparin (hep' a rin) is a complex mixture of naturally occurring glycosaminoglycans that have potent anticoagulant activity. Heparin has been used to treat or prevent venous thromboses for more than 50 years. Multiple generic forms of heparin are available, usually in ampoules or vials of 1000 to 40,000 units per mL. Heparin is typically given initially as 5000 to 10,000 units intravenously, followed by intravenous or subcutaneous boluses every 4 to 12 hours to keep the activated partial thrombin time in the range of 1.5 to 2 times the control value. Common side effects of standard heparin include dizziness, fatigue, headache, indigestion, nausea, excess bleeding, ecchymoses, rash and urticaria.</p>
        </sec>
        <sec id="Heparin.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Heparin has been associated with transient serum aminotransferase elevations in 10% to 60% of patients, but values are usually less than 5 times the upper limit of normal and are rarely associated with symptoms or jaundice. Values above 5 times the upper limit of normal occur in ~2% of those receiving the high doses of heparin. In contrast, serum bilirubin and alkaline phosphatase levels usually do not change. The aminotransferase elevations are usually asymptomatic, mild and self-limited arising within the first 4 to 8 days of therapy and decreasing thereafter, rarely requiring dose modification or discontinuation. In the rare instances of mild, clinically apparent liver injury attributed to heparin reported in the literature, other possible causes of liver injury were usually present (shock, heart failure, sepsis, other potential hepatotoxins). The serum enzyme elevations generally resolve fully within 4 to 10 days of stopping heparin. Allergic features (rash, fever, eosinophilia) and autoantibodies are generally not present.</p>
        </sec>
        <sec id="Heparin.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The cause of the serum aminotransferase elevations during heparin therapy is not known, but it is likely due to a direct hepatotoxic effect on the liver. The elevations may be accompanied by decreases in platelet counts, another know side effect of heparin therapy.</p>
        </sec>
        <sec id="Heparin.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The serum aminotransferase elevations that occur on heparin therapy are usually self-limited and do not require dose modification or discontinuation of therapy. No convincing instances of clinically apparent, severe acute liver injury have been linked to heparin therapy in the published literature.</p>
          <p>References to hepatotoxicity of standard heparin and low molecular weight heparins are given at the end of the overview section entitled Heparins.</p>
          <p>Drug Class: <related-object source-id="livertox" document-id="Anticoagulants">Antithrombotic Agents</related-object>, <related-object source-id="livertox" document-id="Anticoagulants">Anticoagulants</related-object></p>
          <p>Other Drugs in the Subclass, Anticoagulants: <related-object source-id="livertox" document-id="Dabigatran">Dabigatran</related-object>, <related-object source-id="livertox" document-id="Desirudin">Desirudin</related-object>, <related-object source-id="livertox" document-id="Apixaban">Apixaban</related-object>, <related-object source-id="livertox" document-id="Edoxaban">Edoxaban</related-object>, <related-object source-id="livertox" document-id="Fondaparinux">Fondaparinux</related-object>, <related-object source-id="livertox" document-id="Rivaroxaban">Rivaroxaban</related-object>, <related-object source-id="livertox" document-id="Heparins">Heparins</related-object>, <related-object source-id="livertox" document-id="Warfarin">Warfarin</related-object></p>
          <p>Other Drugs in the Subclass, Heparins: <related-object source-id="livertox" document-id="LMW-Heparins">Dalteparin</related-object>, <related-object source-id="livertox" document-id="LMW-Heparins">Enoxaparin</related-object>, <related-object source-id="livertox" document-id="LMW-Heparins">Tinzaparin</related-object></p>
        </sec>
      </sec>
      <sec id="Heparin.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <boxed-text position="anchor" id="Heparin.BPI" orientation="portrait">
          <p>
            <bold>REPRESENTATIVE TRADE NAMES</bold>
          </p>
          <p>Heparin &#x02013; Generic</p>
          <p>
            <bold>DRUG CLASS</bold>
          </p>
          <p>Antithrombotic Agents</p>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Heparin">COMPLETE LABELING</ext-link>
          </p>
          <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
        </boxed-text>
      </sec>
      <sec id="Heparin.CHEMICAL_FORMULA_AND_STRUCTURE">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Heparin.T1" position="anchor" orientation="portrait">
          <table>
            <thead>
              <tr>
                <th id="hd_h_Heparin.T1_1_1_1_1" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Heparin.T1_1_1_1_2" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Heparin.T1_1_1_1_3" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Heparin.T1_1_1_1_4" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Heparin.T1_1_1_1_1" rowspan="1" colspan="1">Heparin</td>
                <td headers="hd_h_Heparin.T1_1_1_1_2" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135346864">9005-49-6</ext-link>
                </td>
                <td headers="hd_h_Heparin.T1_1_1_1_3" rowspan="1" colspan="1">Unspecified</td>
                <td headers="hd_h_Heparin.T1_1_1_1_4" rowspan="1" colspan="1">No Structure</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Heparin.OTHER_REFERENCE_LINKS" sec-type="link-group">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Heparin/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)">Recent References on Heparin: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Heparin">Trials on Heparin: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
